Skip to main content Back to Top
Advertisement

11/10/2016

Zolpidem Tartrate Immediate Release Tablets

Products Affected - Description

    • Zolpidem Tartrate immediate release tablet, Aurobindo, 10 mg, 100 count, NDC 65862-0160-01
    • Zolpidem Tartrate immediate release tablet, Aurobindo, 10 mg, 500 count, NDC 65862-0160-05
    • Zolpidem Tartrate immediate release tablet, Aurobindo, 5 mg, 500 count, NDC 65862-0159-05
    • Zolpidem Tartrate immediate release tablet, Major, 10 mg, 100 count, NDC 00904-6083-61
    • Zolpidem Tartrate immediate release tablet, Major, 5 mg, 100 count, NDC 00904-6082-61

Reason for the Shortage

    • Aurobindo has all presentations listed as inactive.
    • Major discontinued zolpidem tartrate immediate release tablets.
    • Mylan has most zolpidem presentations available.
    • Sandoz has zolpidem available.
    • Torrent has zolpidem available.
    • Sanofi-Aventis has Ambien available.

Available Products

    • Ambien immediate release tablet, Sanofi-Aventis, 10 mg, 100 count, NDC 00024-5421-31
    • Ambien immediate release tablet, Sanofi-Aventis, 10 mg, 500 count, NDC 00024-5421-50
    • Zolpidem Tartrate immediate release tablet, Mylan, 10 mg, 100 count, NDC 00378-5310-01
    • Zolpidem Tartrate immediate release tablet, Mylan, 10 mg, 500 count, NDC 00378-5310-05
    • Zolpidem Tartrate immediate release tablet, Mylan, 5 mg, 100 count, NDC 00378-5305-01
    • Zolpidem Tartrate immediate release tablet, Mylan, 5 mg, 500 count, NDC 00378-5305-05
    • Zolpidem Tartrate immediate release tablet, Mylan Institutional, 10 mg, unit-dose 100 count, NDC 51079-0725-20
    • Zolpidem Tartrate immediate release tablet, Mylan Institutional, 5 mg, unit-dose 100 count, NDC 51079-0724-20
    • Zolpidem Tartrate immediate release tablet, Sandoz, 10 mg, 100 count, NDC 00781-5318-01
    • Zolpidem Tartrate immediate release tablet, Sandoz, 10 mg, 500 count, NDC 00781-5318-10
    • Zolpidem Tartrate immediate release tablet, Sandoz, 5 mg, 100 count, NDC 00781-5317-01
    • Zolpidem Tartrate immediate release tablet, Sandoz, 5 mg, 500 count, NDC 00781-5317-10
    • Zolpidem Tartrate immediate release tablet, Teva, 10 mg, 100 count, NDC 00093-0074-01
    • Zolpidem Tartrate immediate release tablet, Teva, 5 mg, 100 count, NDC 00093-0073-01
    • Zolpidem Tartrate immediate release tablet, Torrent, 10 mg, 100 count, NDC 13668-0008-01
    • Zolpidem Tartrate immediate release tablet, Torrent, 10 mg, 500 count, NDC 13668-0008-05
    • Zolpidem Tartrate immediate release tablet, Torrent, 10 mg, 1000 count, NDC 13668-0008-10
    • Zolpidem Tartrate immediate release tablet, Torrent, 5 mg, 100 count, NDC 13668-0007-01
    • Zolpidem Tartrate immediate release tablet, Torrent, 5 mg, 500 count, NDC 13668-0007-05
    • Zolpidem Tartrate immediate release tablet, Torrent, 5 mg, 1000 count, NDC 13668-0007-10
    • Zolpidem Tartrate immediate release tablet, Torrent, 5 mg, 1500 count, NDC 13668-0007-15

Estimated Resupply Dates

    • All marketed presentations are available.

Updated

Updated November 10, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 10, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT